No Data
Chengdu Easton Biopharmaceuticals (688513.SH): Extends the deadline for share repurchases by six months.
On August 13, Gelunhui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company held the 21st meeting of the third board of directors on August 13, 2024, and approved the "Proposal to Extend the Implementation Period of Share Repurchase". The share repurchase implementation period was extended for 6 months, until February 14, 2025, and the repurchase implementation period was from August 15, 2023 to February 14, 2025.
Chengdu Easton Biopharma Gets Nod to Register Compound Glycyrrhizin Tablets
Chengdu Easton Biopharmaceuticals (688513.SH): Compound Glycyrrhizin Tablets Obtains Pharmaceutical Registration Certificate.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company has recently received approval from the National Medical Products Administration for...
Chengdu Easton Biopharmaceuticals (688513.SH): has repurchased 1.8788% of the company's shares.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on August 2nd that as of the end of July 2024, the company had repurchased a total of 3,316,769 shares through centralized bidding transactions, accounting for 1.8788% of the current total share capital. The highest purchase price was 56.05 yuan/share and the lowest was 28.12 yuan/share, with a total transaction amount of RMB 123,694,177.73 (excluding stamp duty, transaction commission and other trading costs).
Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Market Cap Increased by CN¥513m, Insiders Receive a 49% Cut
Chengdu Easton Biopharmaceuticals' Ubenimex Capsules Passes Regulatory Evaluation
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E RatioNo Data
